Active ingredients: aflibercept
What it is used for
EYLEA (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet AMD); - visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO); - diabetic macular oedema (DME); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO); - visual impairment due to myopic choroidal neovascularisation (myopic CNV)
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Intravitreal-Within The Vitreous Cavity Of The Eye
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Lifetime is 24 Months.
Always read the label. If symptoms persist see your healthcare professional.
EYLEA is a sterile, clear, colourless to pale yellow, preservative-free, iso-osmotic aqueous 40 mg/mL solution for intravitreal injection.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient aflibercept
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)
Eylea Intravitreal injection - myDr.com.au
Eylea Intravitreal injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion | Cochrane
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion
Read more on Cochrane (Australasian Centre) website